AstraZeneca-Bristol Myers Talks Spark Share Moves, Analyst Skepticism

AstraZeneca shares fell sharply Monday after reports emerged that the British drugmaker had held preliminary talks about a potential takeover of US rival Bristol Myers Squibb. The proposed combination would create a pharmaceutical giant valued near 400 billion dollars and rank among the largest such deals in history. AstraZeneca stock dropped as much as 7 percent in London trading before settling around 4.7 percent lower, pulling down the broader FTSE 100 index. Bristol Myers shares rose about 6 percent in premarket action in New York.

Neither company confirmed the discussions. AstraZeneca declined to comment, and Bristol Myers offered no immediate response. Sources cited by the Financial Times indicated that any agreement remains far from certain and could ultimately fall apart. Still, the mere possibility of the transaction left market watchers scratching their heads over why a company enjoying strong momentum would pursue such a move.

Under chief executive Pascal Soriot, AstraZeneca has built one of the industry's most robust pipelines and set an ambitious target of 80 billion dollars in annual sales by 2030. Its market value had climbed steadily to around 264 billion dollars before the news broke. Bristol Myers, by contrast, carries a capitalization of roughly 133 billion dollars and faces looming patent expirations on key products including the blood thinner Eliquis and cancer drug Opdivo. Growth at the New Jersey firm is expected to slow starting next year as generics erode its top sellers.

Analysts described the reported talks as puzzling. Some noted that AstraZeneca could acquire promising assets on its own rather than absorb an entire competitor facing headwinds. Others pointed to significant regulatory scrutiny that would likely follow, given the overlap in both companies' oncology portfolios. A completed deal would expand AstraZeneca's US footprint at a time when the company is already committing 50 billion dollars to American research and manufacturing through 2030. It also comes shortly after AstraZeneca completed a direct listing on the New York Stock Exchange in June.

For Britain, the development raises familiar questions about the future of one of its largest listed companies. AstraZeneca ranks as the second-biggest firm on the London exchange, and any shift toward greater US integration could accelerate concerns about corporate headquarters and decision-making drifting away from the UK. Investors appeared to price in that uncertainty immediately, sending shares lower even as Bristol Myers stock gained ground.

The episode fits a broader pattern of consolidation across the pharmaceutical sector. Large players continue to combine amid rising development costs and pricing pressures, yet the benefits to patients or national economies often remain unclear. With details still sparse, the market reaction suggests many remain unconvinced that this particular pairing serves either company's long-term interests or those of the people who rely on their medicines.